SN2: bimolecular nucleophilic substitution - Updated 2024!

This is probably the easiest among the four. What happens in this reaction is:

a nucleophile attacks
a leaving group leaves 

which happens all at the same time.

We call this a concerted reaction. There is a transition state only and no intermediate is formed. Note that the carbon is electrophilic as it is next to a halogen which is electronegative.

A general form of the mechanism: 

 Here X represents a halogen; a halogen is always a decent leaving group.

Look at the red arrows as the electron flow: the nucleophile attacks from the back side of the molecule and the halogen leaves all in one step.
We can see that the nucleophile can never be on the same side as the leaving group was. (a nucleophile cannot attack the same side as the leaving group leaves, they will crashhh together!)

As I mentioned, there is a transition state. And it is where the nucleophile almost forms a bond with the carbon while leaving group almost leaves the carbon. The transition state is an abstract state; You can't pause the reaction and extract the molecule while it is in the transition state. 

The following is the transition state, not the product. Notice that the carbon almost form a 5 bonds structure.


⏰ Take the chart with you

Download the remastered SN1 · SN2 · E1 · E2 comparison chart as a free, printable five-minute sheet — the classic Chemistery chart, rebuilt.

Get it free →

Also taking gen chem? The full 5 Minutes in Chemistry series covers advanced-level high school & first-year chemistry the same way — 3 volumes, 56 sheets, $19.99 $9.99 until Sep 15. See the series →

Comments

Post a Comment

Popular posts from this blog

What is Pepsin?

Image
In Your Body... Pepsin is a digestive enzyme that performed the best in the acidic condition (pH 2) produced by the gastric juice. It digests and breaks down protein (e.g. meat, seeds, eggs, dairy products, etc.). Keep in mind that pepsin digests proteins (not carbohydrates, not fat) into peptides. These peptides are then either absorbed in the intestine or further break down by enzymes from pancreas. In small intestine (pH around 7), pepsin is no longer effective and no longer digests proteins. Hormones Hormones that regulate digestion and hunger such as gastrin and secretin stimulates the production of pepsinogen, the proenzyme of pepsin. In other words, when pepsinogen is activated, it becomes pepsin.
Read more

The structure of Chimeric Antigen Receptor (CAR) III - Transmembrane Domains

Image
Transmembrane Domains Among the four components of a chimeric antigen receptor (CAR), the transmembrane domain is the least studied one. How different transmembrane domains affect and contribute to each other's functions is also not well studied. That being said, we will go through the function of a transmembrane domain of a CAR, the CD3ζ transmembrane domain, and the CD8α transmembrane domain.  Introduction of the transmembrane domain The transmembrane domain is where the transmembrane proteins are located. In a CAR, the transmembrane domain has the function to anchor the CAR to the T cell membrane. How strong the CAR is anchored to the T cell membrane affects the CAR expression level and stability.  Currently, the commonly used transmembrane domain is derived from proteins such as CD3ζ, CD4, CD8α, and CD28. The CD3ζ transmembrane domain Among the transmembrane domains mentioned, the CD3ζ transmembrane may improve CAR-mediated T cell action as the CD3ζ transmembrane medi...
Read more

Current Limitations of CAR-T Cell Therapy I - Antigen Escape

Image
Antigen Escape Antigen Escape is one of the most concerning challenges during the clinical development of CAR-T cell therapy. A robust initial response is often followed by a relapse in many trials. This is often due to the downregulation or the complete loss of target antigens on the tumor cells. Introduction Antigen escape describes the development of tumor resistance to a single antigen targeting CAR construct. After the initial encounter with the CAR-T cells, the malignant cells mutate and show partial or complete loss of the target antigen expression.  In patients with ALL treated with CD19-targeted CAR-T cell therapy, a downregulation or loss of CD19 antigens was observed.  In patients with myeloma treated with BCMA-targeted CAR-T cell therapy, a downregulation or loss of BCMA expression was observed.  In patients with glioblastoma, a solid tumor treated with IL13Ra2-targeted CAR-T cell therapy, a downregulation of IL13Ra2 expression was observed.  Improve...
Read more